Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 93 articles: HTML format

Single Articles

July 2022
1. NGUYEN DT, Yang W, Renganathan A, Weimholt C, et al
   Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer.
   Clin Cancer Res. 2022 Jul 18. pii: 707054. doi: 10.1158/1078-0432.CCR-21-3603.
   PubMed     Abstract available
   
   
   
2. AGGARWAL R, Starodub AN, Koh BD, Xing G, et al
   Phase 1b Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
   Clin Cancer Res. 2022 Jul 11. pii: 706956. doi: 10.1158/1078-0432.CCR-22-0175.
   PubMed     Abstract available
   
   
   
3. WANG T, Song W, Chen Y, Chen R, et al
   Correction: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.
   Clin Cancer Res. 2022;28:2970.
   PubMed    
   
   
   June 2022
4. SOWALSKY AG, Figueiredo I, Lis RT, Coleman I, et al
   Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer.
   Clin Cancer Res. 2022 Jun 13. pii: 704873. doi: 10.1158/1078-0432.CCR-22-0851.
   PubMed     Abstract available
   
   
   
5. CHAKRABORTY G, Nandakumar S, Hirani R, Nguyen B, et al
   The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer.
   Clin Cancer Res. 2022 Jun 7. pii: 699404. doi: 10.1158/1078-0432.CCR-21-4272.
   PubMed     Abstract available
   
   
   
6. CHOUDHURY AD, Higano CS, de Bono JS, Cook N, et al
   A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kbeta/delta, in Patients with Advanced Solid Tumors.
   Clin Cancer Res. 2022;28:2257-2269.
   PubMed     Abstract available
   
   
   May 2022
7. ZHAO N, Chopra S, Trepka K, Wang YH, et al
   CUB domain containing protein 1 (CDCP1) is a target for radioligand therapy in castration resistant prostate cancer including PSMA null disease.
   Clin Cancer Res. 2022 May 23. pii: 699115. doi: 10.1158/1078-0432.CCR-21-3858.
   PubMed     Abstract available
   
   
   
8. COLEMAN IM, DeSarkar N, Morrissey C, Xin L, et al
   Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer.
   Clin Cancer Res. 2022 May 12. pii: 698880. doi: 10.1158/1078-0432.CCR-21-4289.
   PubMed     Abstract available
   
   
   
9. SHEEHAN B, Neeb A, Buroni L, Paschalis A, et al
   Prostate Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.
   Clin Cancer Res. 2022 May 12. pii: 698876. doi: 10.1158/1078-0432.CCR-21-4531.
   PubMed     Abstract available
   
   
   April 2022
10. MARKOWSKI MC, Tutrone R, Pieczonka C, Barnette KG, et al
    A Phase 1b/2 Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men With Metastatic Castration-Resistant Prostate Cancer with Progression on an Androgen Receptor Targeting Agent.
    Clin Cancer Res. 2022 Apr 13. pii: 694403. doi: 10.1158/1078-0432.CCR-22-0162.
    PubMed     Abstract available
    
    
    
11. SWEENEY CJ, Percent IJ, Babu S, Cultrera JL, et al
    Phase 1b/2 Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694115. doi: 10.1158/1078-0432.CCR-21-2326.
    PubMed     Abstract available
    
    
    
12. WESTPHALEN CB, Fine AD, Andre F, Ganesan S, et al
    Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Clin Cancer Res. 2022;28:1412-1421.
    PubMed     Abstract available
    
    
    February 2022
13. DE KOUCHKOVSKY I, Rao A, Carneiro BA, Zhang L, et al
    A phase Ib/II study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 17. pii: 681559. doi: 10.1158/1078-0432.CCR-21-4302.
    PubMed     Abstract available
    
    
    
14. SERRITELLA AV, Shevrin D, Heath EI, Wade JL, et al
    Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-4049.
    PubMed     Abstract available
    
    
    January 2022
15. HUSSAIN M, Corcoran C, Sibilla C, Fizazi K, et al
    Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-3940.
    PubMed     Abstract available
    
    
    
16. DYLGJERI E, Kothari V, Shafi AA, Semenova G, et al
    A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Jan 25. pii: 1078-0432.CCR-21-1846.
    PubMed     Abstract available
    
    
    December 2021
17. ZHAO JL, Fizazi K, Saad F, Chi KN, et al
    The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1090.
    PubMed     Abstract available
    
    
    
18. BERCHUCK JE, Baca SC, McClure HM, Korthauer K, et al
    Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-3762.
    PubMed     Abstract available
    
    
    November 2021
19. PENG S, Hu P, Xiao YT, Lu W, et al
    Single-cell analysis reveals EP4 as a target for restoring T cell infiltration and sensitizing prostate cancer to immunotherapy.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-0299.
    PubMed     Abstract available
    
    
    
20. AL-UBAIDI FLT, Schultz N, Loseva O, Egevad L, et al
    Editor's Note: Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer.
    Clin Cancer Res. 2021;27:6066.
    PubMed    
    
    
    October 2021
21. DORFF TB, Narayan V, Forman SJ, Zang PD, et al
    Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer.
    Clin Cancer Res. 2021 Oct 21. pii: 1078-0432.CCR-21-1483.
    PubMed     Abstract available
    
    
    
22. STOPSACK KH, Nandakumar S, Arora K, Nguyen B, et al
    Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2577.
    PubMed     Abstract available
    
    
    
23. LOEHR A, Patnaik A, Campbell D, Shapiro J, et al
    Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
    Clin Cancer Res. 2021 Oct 1. pii: 1078-0432.CCR-21-2199.
    PubMed     Abstract available
    
    
    September 2021
24. ZHANG H, Orme JJ, Abraha F, Stish BJ, et al
    Phase II evaluation of Stereotactic Ablative Radiotherapy (SABR) and immunity in (11)C-Choline-PET/CT-identified oligometastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-2510.
    PubMed     Abstract available
    
    
    
25. MIZUNO K, Sumiyoshi T, Okegawa T, Terada N, et al
    Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-2328.
    PubMed     Abstract available
    
    
    
26. JEONG IG, Lim B, Yun SC, Lim JH, et al
    Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial.
    Clin Cancer Res. 2021;27:5004-5011.
    PubMed     Abstract available
    
    
    August 2021
27. MOSTAGHEL EA, Marck BT, Kolokythas O, Chew F, et al
    Circulating and intra-tumoral adrenal androgens correlate with response to abiraterone in men with castration resistant prostate cancer.
    Clin Cancer Res. 2021 Aug 18. pii: 1078-0432.CCR-21-1819.
    PubMed     Abstract available
    
    
    July 2021
28. MURTOLA TJ, Siltari A
    Statins for prostate cancer: when and how much?
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1891.
    PubMed     Abstract available
    
    
    
29. SARKER D, Dawson NA, Aparicio AM, Dorff TB, et al
    A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1115.
    PubMed     Abstract available
    
    
    
30. BROWN LC, Halabi S, Schonhoft JD, Yang Q, et al
    Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
    Clin Cancer Res. 2021;27:4077-4088.
    PubMed     Abstract available
    
    
    
31. DE BONO JS, Fleming MT, Wang JS, Cathomas R, et al
    Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
    Clin Cancer Res. 2021;27:3602-3609.
    PubMed     Abstract available
    
    
    June 2021
32. TURNER PG, Jain S, Cole A, Grey A, et al
    Toxicity and efficacy of concurrent androgen deprivation therapy, pelvic radiotherapy, and radium-223 in patients with de-novo metastatic hormone sensitive prostate cancer.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0685.
    PubMed     Abstract available
    
    
    
33. CALAGUA C, Ficial M, Jansen CS, Hirz T, et al
    A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-0121.
    PubMed     Abstract available
    
    
    
34. TANG Z, Pilie PG, Geng C, Manyam GC, et al
    ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-1010.
    PubMed     Abstract available
    
    
    
35. KIM DH, Sun D, Storck WK, Welker Leng KR, et al
    BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
    Clin Cancer Res. 2021 Jun 18. pii: 1078-0432.CCR-20-4968.
    PubMed     Abstract available
    
    
    
36. SMITH MR, Thomas S, Gormley M, Chowdhury S, et al
    Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0358.
    PubMed     Abstract available
    
    
    
37. FONG L, Morris MJ, Sartor O, Higano CS, et al
    A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0063.
    PubMed     Abstract available
    
    
    
38. ANNALA M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, et al
    Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1625.
    PubMed     Abstract available
    
    
    
39. HAWKEY NM, Armstrong AJ
    Liquid Biopsy: It's the Bloody Truth!
    Clin Cancer Res. 2021;27:2961-2963.
    PubMed     Abstract available
    
    
    
40. HEGDE A, Jayaprakash P, Couillault CA, Piha-Paul S, et al
    A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Clin Cancer Res. 2021;27:3050-3060.
    PubMed     Abstract available
    
    
    May 2021
41. HAMMER S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, et al
    Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) by a dual mode-of-action in prostate cancer models.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0342.
    PubMed     Abstract available
    
    
    
42. MUNN LL, Stylianopoulos T, Jain NK, Hardin CC, et al
    Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.
    Clin Cancer Res. 2021;27:2706-2711.
    PubMed     Abstract available
    
    
    
43. KAWAMOTO K, Okino ST, Place RF, Urakami S, et al
    Editor's Note: Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer.
    Clin Cancer Res. 2021;27:2665.
    PubMed    
    
    
    April 2021
44. TRUE LD, Chen DL
    How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?
    Clin Cancer Res. 2021 Apr 23. pii: 1078-0432.CCR-21-0749.
    PubMed     Abstract available
    
    
    
45. PRIVE BM, Peters SMB, Muselaers CHJ, van Oort IM, et al
    Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer, a prospective pilot study.
    Clin Cancer Res. 2021 Apr 21. pii: 1078-0432.CCR-20-4298.
    PubMed     Abstract available
    
    
    
46. MCKAY RR, Kwak L, Crowdis J, Sperger JM, et al
    Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance.
    Clin Cancer Res. 2021 Apr 13. pii: 1078-0432.CCR-20-4616.
    PubMed     Abstract available
    
    
    March 2021
47. PACHYNSKI RK, Kim E, Miheecheva N, Kotlov N, et al
    Single cell spatial proteomic revelations on the multiparametric MRI heterogeneity of clinically significant prostate cancer.
    Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4217.
    PubMed     Abstract available
    
    
    
48. VARDAKI I, Corn P, Gentile E, Song JH, et al
    Radium 223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4790.
    PubMed     Abstract available
    
    
    
49. PALMBOS PL, Daignault-Newton S, Tomlins SA, Agarwal N, et al
    A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
    Clin Cancer Res. 2021 Mar 16. pii: 1078-0432.CCR-21-0024.
    PubMed     Abstract available
    
    
    
50. FREEDLAND SJ, Allen J, Jarman A, Oyekunle T, et al
    Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
    Clin Cancer Res. 2021;27:1823.
    PubMed    
    
    
    
51. WARNER E, Herberts C, Fu S, Yip S, et al
    BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
    Clin Cancer Res. 2021;27:1650-1662.
    PubMed     Abstract available
    
    
    
52. CHAKRABORTY G, Patail NK, Hirani R, Nandakumar S, et al
    Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
    Clin Cancer Res. 2021;27:1792-1806.
    PubMed     Abstract available
    
    
    
53. KAMAT NV, Yu EY, Lee JK
    BiTE-ing into prostate cancer with bispecific T cell engagers.
    Clin Cancer Res. 2021 Mar 11. pii: 1078-0432.CCR-21-0355.
    PubMed     Abstract available
    
    
    
54. LIN L, Kane N, Kobayashi N, Kono EA, et al
    High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
    Clin Cancer Res. 2021;27:1505-1515.
    PubMed     Abstract available
    
    
    February 2021
55. MORRIS MJ, Rowe SP, Gorin MA, Saperstein L, et al
    Diagnostic Performance of (18)F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.
    Clin Cancer Res. 2021 Feb 23. pii: 1078-0432.CCR-20-4573.
    PubMed     Abstract available
    
    
    
56. PETRYLAK DP, Loriot Y, Shaffer D, Braiteh F, et al
    Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study.
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-1981.
    PubMed     Abstract available
    
    
    
57. TUKACHINSKY H, Madison RW, Chung JH, Gjoerup O, et al
    Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-4805.
    PubMed     Abstract available
    
    
    
58. LIANG Y, Jeganathan S, Marastoni S, Sharp A, et al
    Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-3260.
    PubMed     Abstract available
    
    
    January 2021
59. DEEGEN P, Thomas O, Nolan-Stevaux O, Li S, et al
    The PSMA Targeting Half-Life Extended BiTE((R)) Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-3725.
    PubMed     Abstract available
    
    
    
60. GOLDKORN A, Tangen CM, Plets M, Morrison GJ, et al
    Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216).
    Clin Cancer Res. 2021 Jan 26. pii: 1078-0432.CCR-20-3587.
    PubMed     Abstract available
    
    
    
61. PAN W, Zhang Z, Kimball H, Qu F, et al
    Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells.
    Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-4391.
    PubMed     Abstract available
    
    
    
62. MARSHALL CH, Fu W, Wang H, Park JC, et al
    Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Jan 15. pii: 1078-0432.CCR-20-4476.
    PubMed     Abstract available
    
    
    
63. RESCIGNO P, Gurel B, Pereira R, Crespo M, et al
    Characterizing CDK12-Mutated Prostate Cancers.
    Clin Cancer Res. 2021;27:566-574.
    PubMed     Abstract available
    
    
    
64. VEACH D, Storey CM, Lueckerath K, Braun K, et al
    PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.
    Clin Cancer Res. 2021 Jan 13. pii: 1078-0432.CCR-20-3614.
    PubMed     Abstract available
    
    
    December 2020
65. WANG S, Li J, Hua J, Su Y, et al
    Molecular imaging of prostate cancer targeting CD46 using immunoPET.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-3310.
    PubMed     Abstract available
    
    
    November 2020
66. LOTAN TL, Antonarakis ES
    CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3877.
    PubMed     Abstract available
    
    
    
67. DELUCIA DC, Cardillo TM, Ang LS, Labrecque MP, et al
    Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3396.
    PubMed     Abstract available
    
    
    October 2020
68. AWASTHI S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, et al
    Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer.
    Clin Cancer Res. 2020 Oct 9. pii: 1078-0432.CCR-20-2925.
    PubMed     Abstract available
    
    
    
69. KARZAI F, Walker SM, Wilkinson S, Madan RA, et al
    Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response.
    Clin Cancer Res. 2020 Oct 6. pii: 1078-0432.CCR-20-2344.
    PubMed     Abstract available
    
    
    September 2020
70. CHEN WS, Haynes WA, Waitz R, Kamath K, et al
    Autoantibody landscape in patients with advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 23. pii: 1078-0432.CCR-20-1966.
    PubMed     Abstract available
    
    
    
71. TRIPATHI A, Supko JG, Gray KP, Melnick Z, et al
    Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.
    Clin Cancer Res. 2020 Sep 17. pii: 1078-0432.CCR-20-2306.
    PubMed     Abstract available
    
    
    
72. GAO AC, Armstrong CM, Liu C, Liu L, et al
    Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1682.
    PubMed     Abstract available
    
    
    
73. BORDINI J, Morisi F, Elia AR, Santambrogio P, et al
    Iron induces cell death and strengthens the efficacy of anti-androgen therapy in prostate cancer models.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-3182.
    PubMed     Abstract available
    
    
    August 2020
74. MUNIYAN S, Rachagani S, Parte S, Halder S, et al
    Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-1569.
    PubMed     Abstract available
    
    
    
75. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
    Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
    PubMed     Abstract available
    
    
    July 2020
76. SHENDEROV E, Antonarakis ES
    Reimagining vaccines for prostate cancer: Back to the future.
    Clin Cancer Res. 2020 Jul 31. pii: 1078-0432.CCR-20-2257.
    PubMed     Abstract available
    
    
    
77. GUAN X, Sun D, Lu E, Urrutia JA, et al
    Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 29. pii: 1078-0432.CCR-19-2303.
    PubMed     Abstract available
    
    
    
78. PARK SY, Na SJ, Kumar M, Mosci C, et al
    Clinical evaluation of (4S)-4-(3-[(18)F]Fluoropropyl)-L-glutamate ((18)F-FSPG) for PET/CT imaging in patients with newly diagnosed and recurrent prostate cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0644.
    PubMed     Abstract available
    
    
    
79. AGGARWAL RR, Schweizer MT, Nanus DM, Pantuck AJ, et al
    A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1707.
    PubMed     Abstract available
    
    
    
80. KAUR H, Salles DC, Murali S, Hicks JL, et al
    Genomic and Clinical-Pathologic Characterization of ATM-deficient Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0764.
    PubMed     Abstract available
    
    
    
81. HINTZ HM, Gallant JP, Vander Griend DJ, Coleman I, et al
    Imaging Fibroblast Activation Protein Alpha improves diagnosis of metastatic Prostate Cancer with Positron Emission Tomography.
    Clin Cancer Res. 2020 Jul 7. pii: 1078-0432.CCR-20-1358.
    PubMed     Abstract available
    
    
    June 2020
82. PALANISAMY N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, et al
    The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development.
    Clin Cancer Res. 2020 Jun 23. pii: 1078-0432.CCR-20-0479.
    PubMed     Abstract available
    
    
    
83. PEREZ-RUIXO C, Ackaert O, Ouellet D, Chien C, et al
    Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-20-1041.
    PubMed     Abstract available
    
    
    
84. RAVI KUMAR AS, Hofman MS
    Mechanistic Insights for Optimizing PSMA Radioligand Therapy.
    Clin Cancer Res. 2020;26:2774-2776.
    PubMed     Abstract available
    
    
    
85. CURRENT K, Meyer C, Magyar CE, Mona CE, et al
    Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.
    Clin Cancer Res. 2020;26:2946-2955.
    PubMed     Abstract available
    
    
    
86. WANG B, Liu C, Wei Y, Meng J, et al
    A prospective trial of (68)Ga-PSMA and (18)F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration.
    Clin Cancer Res. 2020 Jun 11. pii: 1078-0432.CCR-20-0587.
    PubMed     Abstract available
    
    
    
87. KYRIAKOPOULOS CE, Eickhoff J, Ferrari AC, Schweizer MT, et al
    Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jun 8. pii: 1078-0432.CCR-20-0945.
    PubMed     Abstract available
    
    
    May 2020
88. POSADAS EM, Chi KN, de Wit R, de Jonge MJA, et al
    Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study.
    Clin Cancer Res. 2020 May 4. pii: 1078-0432.CCR-19-3402.
    PubMed     Abstract available
    
    
    April 2020
89. MALIHI PD, Graf RP, Rodriguez A, Ramesh N, et al
    Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-4100.
    PubMed     Abstract available
    
    
    
90. MANDIGO AC, Knudsen KE
    Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes.
    Clin Cancer Res. 2020;26:1784-1786.
    PubMed     Abstract available
    
    
    
91. BRAVE M, Weinstock C, Brewer JR, Chi DC, et al
    An FDA Review of Drug Development in Non-Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Apr 13. pii: 1078-0432.CCR-19-3835.
    PubMed     Abstract available
    
    
    March 2020
92. SOKOLOVA AO, Yu EY, Cheng HH
    Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity.
    Clin Cancer Res. 2020 Mar 31. pii: 1078-0432.CCR-20-0707.
    PubMed     Abstract available
    
    
    
93. STOPSACK KH, Nandakumar S, Wibmer AG, Haywood S, et al
    Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-20-0168.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: